spacer
home > pmps > winter 2002 > nasal delivery of vaccines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Delivery of Vaccines

The nasal delivery of vaccines has recently emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. The mucosal immune response is rapid and nasal vaccines may also induce protection in distant mucosal sites. Correct formulation and adequate distribution to the nasal mucosa are, however, essential for efficacy and safety. The complexity of nasal geometry represents a major challenge for efficient intranasal vaccination, and current delivery devices may prove inadequate in meeting future safety and reliability requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS
Dr Per Gisle Djupesland is Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing devices based on a novel technology for the nasal delivery of drugs and vaccines. Dr Djupesland is a specialist in Otorhinolaryngology.

He has a PhD in Nasal Physiology and Aerodynamics from the University of Oslo and has also been Research Fellow at the University of Toronto, Canada. Dr Djupesland holds a degree in International Health and Tropical Medicine from the University of Pierre and Marie Curie in Paris, France, and has been Project Manager for a large-scale vaccination trial for the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement